Olverembatinib for FGFR1-rearranged Neoplasms

Sponsor
The First Affiliated Hospital of Soochow University
Study ID
NCT05521204
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Leukemia
  • Myeloproliferative Neoplasm

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olverembatinib — DRUG
    Given PO

Study Details

FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.

Key Dates

First listed
Aug 30, 2022
Start date
Sep 1, 2022
Status verified
Aug 2022
Primary completion
Aug 31, 2024
Completion
Aug 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group

Primary Outcome Measure

Overall Response Rate [ Time Frame: Assessed at protocol-defined timepoints through end of study, up to approximately 48 months. ]

Central Contacts

Related Studies